Navigation Links
Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
Date:12/6/2012

MAYWOOD, Il. - A groundbreaking clinical trial involving the breast cancer drug tamoxifen should prompt certain breast cancer patients to reconsider their treatment options, according to Loyola University Medical Center breast cancer specialist Dr. Kathy Albain.

The trial is called ATLAS (Adjuvant Tamoxifen Longer Against Shorter). It included women with estrogen receptor-positive breast cancer that had not spread to distant organs. Women who took tamoxifen for 10 years had a lower risk of recurrence and lower mortality rate than women who took the drug for 5 years, which is the current standard of care.

"I think this is going to create a need for women with this type of breast cancer to readdress their treatment options," Albain said.

Dr. Richard Gray, on behalf of the ATLAS trial investigators, announced results Dec. 5 during the San Antonio Breast Cancer Symposium. Albain moderated the opening oral session in which the results were announced and discussed.

A worldwide team of investigators enrolled 6,846 women with estrogen receptor-positive breast cancer who had been taking tamoxifen for five years and were free of recurrence of their breast cancer. Women were randomly assigned to either stop taking tamoxifen, or to continue taking the drug for another five years.

During the second decade following diagnosis, women who continued taking tamoxifen had a 25 percent lower recurrence rate and a 29 percent lower breast cancer mortality rate, compared with women who stopped after five years. Overall, taking tamoxifen for 10 years cut the risk of dying of breast cancer in half.

Albain noted there are risks to taking tamoxifen, including a higher risk of endometrial cancer in postmenopausal patients and an increased risk of blood clots. But endometrial cancer generally is curable, and in certain women, the benefits of taking tamoxifen for longer periods may outweigh the risks, Albain said.

Premenopausal women may benefit by taking tamoxifen for 10 years rather than 5 years, Albain said. The picture is more complicated for postmenopausal women. Depending on the patient, a regimen could involve taking tamoxifen for a period of time and an aromatase inhibitor for a period of time.

"Each woman's situation is different, which is why she should consult her doctor on the best course of action in light of these exciting and significant new findings," Albain said.


'/>"/>
Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Possible therapy for tamoxifen resistant breast cancer identified
2. New finding gives clues for overcoming tamoxifen-resistant breast cancer
3. 10 Years of Tamoxifen Better Than 5: Study
4. Brain Tumor Vaccine Shows Promise in Early Trial
5. URMC clinical trial tests new regimen for hypertension
6. Analysis Finds Clinical Trials Often Small, of Poor Quality
7. US spends far more for health care than 12 industrialized nations, but quality varies
8. New Weight-Loss Drug Shows Promise in Trial
9. Palpitations are predictive of future atrial fibrillation
10. Trial Set to See if Drug Can Prevent Alzheimers
11. Experts call for clinical trials to test non-skeletal benefits of vitamin D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... ... 2017 , ... The Military Officers Association of America (MOAA) announced its support ... retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the staff director ... with the issues and challenges veterans face with the VA. Following a 30-year career ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening ... 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned ... owns three other locations in the Topeka and Bonner Springs, Kan. area. , ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South ... selected 21 leaders from government, business and civil society in 11 countries across the ... this fall, engaging in a transformative exchange of knowledge and ideas with the leading ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
Breaking Medicine Technology: